Close Menu

Sponsored

By
CooperSurgical

A recent study demonstrated a significant increase in pregnancy and live birth rates associated with the use of artificial intelligence-assisted genetic testing technology alongside in vitro fertilization.

By
F. Hoffmann-La Roche Ltd.

The COVID-19 pandemic has caused massive disruption to cancer care. Delays in diagnosis and treatment highlight the importance of establishing a personalized healthcare approach that provides tailored care, integrates innovation, and supports equal access to cancer care.

By
ATCC
A scientist in the lab

As America’s first repository of microorganisms and other biomaterials, ATCC has a steeped history as one of the pillars of infectious disease research. Recognizing that many researchers are just now getting back to the lab, the organization is sharing what it has learned over the past several months about best practices for keeping workers safe.

Advances in quantitative proteomics have great potential to improve cancer research and treatment by uncovering and validating novel drug targets, helping to understand drug mechanisms of action, and searching for new diagnostic, prognostic, or predictive biomarkers. 

Several examples of this innovation were on display at the recent American Association for Cancer Research Virtual Annual Meeting, where Biognosys published seven posters highlighting the utility of its next-generation proteomics platform in oncology.

Michiel Weber, Senior Bioinformatician at DDL (left), and A. Sinan Yavuz, PhD, Senior Bioinformatics Scientist, Seven Bridges (right)

Researchers worldwide are racing to address COVID-19, working on diagnostics, therapies, and vaccines to control the virus. To support these efforts, DDL Diagnostic Laboratory is developing faster ways to identify viral genomic variants – work that was accelerated by a collaboration with bioinformatics provider Seven Bridges.

By
ATCC

A recent study, commissioned by ATCC, sheds new light on the challenges of research reproducibility. Pressure to publish, inadequate study design, and bias toward publishing positive results are all major contributors to the problem. Fortunately, identifying these issues is an important step towards improving them. To some degree, this is a cultural issue within the scientific community, and an attitudinal shift is necessary to solve it.

Bloomberg reports AstraZeneca may conduct another study of its candidate SARS-CoV-2 vaccine after dosing error.

Moderna is applying for an Emergency Use Authorization for its coronavirus vaccine, according to the New York Times.

The National Health Service is to conduct a trial of Grail's blood-based screening test for cancer.

In PLOS this week: somatic mutation patterns of glioblastomas among Lebanese patients, phenome-wide study using UK Biobank data, and more.